Merkel cell carcinoma in Turkey: A multicentric study

Basit Öğe Kaydı
dc.authorid0000-0002-0443-6966
dc.contributor.authorYıldız, Fatih
dc.contributor.authorDemirci, Umut
dc.contributor.authorKüçükarda, Ahmet
dc.contributor.authorBüyükşimşek, Mahmut
dc.contributor.authorSakalar, Teoman
dc.contributor.authorÖztürk Topçu, Türkan
dc.contributor.authorAslan, Ferit
dc.contributor.authorTufan, Gülnihal
dc.contributor.authorAydın, Övgü
dc.contributor.authorTurna, Hande
dc.contributor.authorAkgül Babacan, Nalan
dc.contributor.authorBaşoğlu, Tugba
dc.contributor.authorKurt, Bediz
dc.contributor.authorYıldız, Birol
dc.contributor.authorEren, Tülay
dc.contributor.authorDemiray, Atike Gökçen
dc.contributor.authorGümüşay, Özge
dc.contributor.authorArslan, Çağatay
dc.contributor.authorÖzdemir, Nuriye
dc.contributor.authorÜrün, Yüksel
dc.contributor.authorBaykara, Meltem
dc.contributor.authorTuran, Nedim
dc.contributor.authorUysal, Mükremin
dc.contributor.authorBilici, Ahmet
dc.contributor.authorKavgacı, Halil
dc.contributor.authorÇiçin, İrfan
dc.contributor.authorKılıçkap, Saadettin
dc.contributor.authorPaydaş, Semra
dc.date.accessioned2022-01-04T10:21:33Z
dc.date.available2022-01-04T10:21:33Z
dc.date.issued2021
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalı
dc.description.abstractBackground: Merkel cell carcinoma (MCC) is a rare but highly aggressive neuroendocrine carcinoma of the skin. In this study, we aimed to evaluate the clinicopathologic characteristics, treatment outcomes, and survival of MCC cases in Turkey. Materials and methods: The patients diagnosed with MCC between 1999 and 2018 at twenty different centers in Turkey were included in the study. Patient and tumor characteristics and adjuvant and metastatis treatment outcomes were analyzed retrospectively. Results: The median age of totally 89 patients was 70 (26-93). The most common primary location was lower limbs (n = 29, 32.5%). Immunohistochemically, CK20 positivity was present in 59 patients (66.3%). Only two patients had secondary malignancy. The majority of the patients (n = 76, 85.4%) were diagnosed at the localized stage. Surgery was performed for all patients in the early stage, and adjuvant radiotherapy or/and chemotherapy was applied to 52.6% (n = 40) of nonmetastatic patients. The median follow-up was 29 months. Recurrence developed in 21 (27.6%) of the 76 patients who presented with local or regional disease. Two-year disease-free survival (DFS) was 68.1% and 5-year DFS was 62.0% for localized stage. The 5-year DFS was similar for patients receiving adjuvant treatment (chemotherapy, radiotherapy, or sequential chemoradiotherapy) and without adjuvant therapy (P > 0.05). Two-year overall survival in patients who presented with localized disease was 71.3% and 18.5% in metastatic patients (P < 0.001). In the metastatic stage, platinum/etoposide combination was the most preferred combination regimen. Median progression-free survival (PFS) in first-line chemotherapy was 7 months (95% confidence interval: 3.5-10.5 months; standart error: 1.78). Conclusions: Although MCC is rare in Turkey, the incidence is increasing. Gender, CK20 status, tumor size, lymph node involvement, and adjuvant treatment were not associated with recurrence.
dc.identifier.citationYıldız, F., Demirci, U., Küçükarda, A., Büyükşimşek, M., Sakalar, T. Öztürk Topçu, T. ... Paydaş, S. (2021). Merkel cell carcinoma in Turkey: A multicentric study. Journal of Cancer Research and Therapeutics, 17(6), 1525-1529. https://dx.doi.org/10.4103/jcrt.JCRT_950_19
dc.identifier.doi10.4103/jcrt.JCRT_950_19
dc.identifier.endpage1529
dc.identifier.issn0973-1482
dc.identifier.issn1998-4138
dc.identifier.issue6
dc.identifier.scopusqualityQ3
dc.identifier.startpage1525
dc.identifier.urihttps://dx.doi.org/10.4103/jcrt.JCRT_950_19
dc.identifier.urihttps://hdl.handle.net/20.500.12511/8757
dc.identifier.volume17
dc.identifier.wosWOS:000754558000034en_US
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherWolters Kluwer Medknow Publications
dc.relation.ispartofJournal of Cancer Research and Therapeuticsen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsAttribution-NonCommercial-ShareAlike 4.0 International*
dc.rightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttps://creativecommons.org/licenses/by-nc-sa/4.0/*
dc.subjectCK20
dc.subjectMerkel Cell Carcinoma
dc.subjectNeuroendocrin Carcinoma
dc.subjectSkin Carcinoma
dc.titleMerkel cell carcinoma in Turkey: A multicentric study
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
Bilici-Ahmet-2021.pdf
Boyut:
834.23 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu